Cargando…

The 2014–2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States

Objective This article aims to compare respiratory syncytial virus (RSV) immunoprophylaxis (IP) use and RSV hospitalization rates (RSVH) in preterm and full-term infants without chronic lung disease of prematurity or congenital heart disease before and after the recommendation against RSV IP use in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kong, Amanda M., Krilov, Leonard R., Fergie, Jaime, Goldstein, Mitchell, Diakun, David, Wade, Sally W., Pavilack, Melissa, McLaurin, Kimmie K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Thieme Medical Publishers 2018
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193366/ https://www.ncbi.nlm.nih.gov/pubmed/28881376 http://dx.doi.org/10.1055/s-0037-1606352

Ejemplares similares

Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics
por: Krilov, Leonard R., et al.
Publicado: (2020)

Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017
por: Fergie, Jaime, et al.
Publicado: (2020)

National Bronchiolitis Hospitalization Rates Among Preterm and Full Term Infants: 2010–2015
por: Krilov, Leonard R, et al.
Publicado: (2017)

Modeling the Potential Impact of the 2014 American Academy of Pediatrics Respiratory Syncytial Virus Prophylaxis Guidance on Preterm Infant RSV Outcomes
por: McLaurin, Kimmie K., et al.
Publicado: (2015)

743. Severity and Costs of Respiratory Syncytial Virus and Bronchiolitis Hospitalization in Commercially Insured Preterm and Term Infants Before and After the 2014 American Academy of Pediatrics Guidance Change on Immunoprophylaxis
por: Krilov, Leonard R, et al.
Publicado: (2018)

740. Impact of the 2014 American Academy of Pediatrics Guidance on Respiratory Syncytial Virus Hospitalization Rates for Preterm Infants <29 Weeks Gestational Age at Birth: 2012–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

Impact of the 2014 American Academy of Pediatrics Policy on RSV Hospitalization in Preterm Infants in the United States
por: Goldstein, Mitchell, et al.
Publicado: (2021)

735. Severity and Healthcare Costs of Respiratory Syncytial Virus Hospitalizations in US Preterm Infants Born at 29–34 Weeks Gestation: 2014–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

Unintended Consequences Following the 2014 American Academy of Pediatrics Policy Change for Palivizumab Prophylaxis among Infants Born at Less than 29 Weeks' Gestation
por: Goldstein, Mitchell, et al.
Publicado: (2021)

Impact of Respiratory Syncytial Virus–Confirmed Hospitalizations on Caregivers of US Preterm Infants
por: Pokrzywinski, Robin M., et al.
Publicado: (2019)

Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States
por: Parikh, Rohan C., et al.
Publicado: (2017)

Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants
por: Pavilack, Melissa, et al.
Publicado: (2017)

Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants
por: McLaurin, K K, et al.
Publicado: (2016)

The Logistics and Coordination of Respiratory Syncytial Virus Immunoprophylaxis Use Among US Pediatric Specialists
por: Wong, Pierre C., et al.
Publicado: (2016)

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
por: Shahabi, Ahva, et al.
Publicado: (2017)

Severity and Cost of RSV Hospitalization Among US Preterm Infants Following the 2014 American Academy of Pediatrics Policy Change
por: Krilov, Leonard R., et al.
Publicado: (2021)

Characteristics and health care utilization of otherwise healthy commercially and Medicaid-insured preterm and full-term infants in the US
por: McLaurin, Kimmie K, et al.
Publicado: (2019)

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value
por: Olchanski, Natalia, et al.
Publicado: (2018)

Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32–35 Weeks Gestation Not Receiving Immunoprophylaxis
por: Ambrose, Christopher S., et al.
Publicado: (2014)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
por: Abushahin, Ahmad, et al.
Publicado: (2018)

Immunoprophylaxis of respiratory syncytial virus: global experience
por: Simoes, Eric AF
Publicado: (2002)

Patient equity and respiratory syncytial virus Immunoprophylaxis
por: Cody Meissner, H.
Publicado: (2019)

Seasonality in Respiratory Syncytial Virus Hospitalizations and Immunoprophylaxis
por: Kusma, Jennifer D., et al.
Publicado: (2023)

2638. Respiratory Syncitial Virus Hospitalizations (RSVH) and All-Cause Bronchiolitis Hospitalizations (BH) Among 29–34 Weeks Gestational Age (wGA) Preterm Infants Before and After the 2014 American Academy of Pediatrics (AAP) Immunoprophylaxis Policy Change Using the Children’s Hospital Association’s Pediatric Health Information System (PHIS)
por: Fergie, Jaime, et al.
Publicado: (2019)

Increasing Rates of RSV Hospitalization among Preterm Infants: A Decade of Data
por: Kong, Amanda M., et al.
Publicado: (2021)

Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants
por: Blanken, Maarten O., et al.
Publicado: (2017)

Compliance with The RSV Immunoprophylaxis Dosing Schedule in The Polish Registry for Palivizumab (2008-2014)
por: Borecka, Róża, et al.
Publicado: (2019)

Hospitalizations in the First Year of Life for Infants with Respiratory Syncytial Virus and Unspecified Bronchiolitis in a Population-Based Cohort
por: Lee, Henry, et al.
Publicado: (2017)

Population-based trends and underlying risk factors for infant respiratory syncytial virus and bronchiolitis hospitalizations
por: Bennett, Mihoko V., et al.
Publicado: (2018)

Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants
por: Staebler, Suzanne, et al.
Publicado: (2020)

Immunoprophylaxis against respiratory syncytial virus with palvizumab: what is new?
por: Sáfadi, Marco Aurélio P.
Publicado: (2014)

Trends in Respiratory Syncytial Virus and Bronchiolitis Hospitalization Rates in High-Risk Infants in a United States Nationally Representative Database, 1997–2012
por: Doucette, Abigail, et al.
Publicado: (2016)

Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?
por: Rocca, Alessandro, et al.
Publicado: (2021)

The epidemiology and risk factors of respiratory syncytial virus and its impact on the timing of immunoprophylaxis
por: Jeena, Prakash Mohan
Publicado: (2018)

Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia
por: Fang, Li-Ching, et al.
Publicado: (2023)

Guidance on the use of antiviral drugs for influenza in acute care facilities in Canada, 2014–2015
por: Stiver, H Grant, et al.
Publicado: (2015)

The Medicaid Cost of Palivizumab
por: Ambrose, Christopher S., et al.
Publicado: (2015)

Acknowledgement to reviewers 2014/2015
por: Madry, Henning
Publicado: (2016)

Faculty Seminars 2014/2015
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_j4arke0i676kp2fekf90u8pk4u